The US FDA has approved a new non-opioid painkiller, Journavx, by Vertex Pharmaceuticals, which targets pain signals before reaching the brain to provide relief for moderate to severe pain without the addictive potential of opioids. Clinical trials showed effectiveness in reducing post-surgery pain, marking an important milestone in acute pain management amidst the opioid crisis in the US. Priced at $15.50 per capsule, Journavx is the first new class of pain medicine approved in over 20 years, offering hope for the 80 million Americans prescribed pain medication annually.
Full Article
US banks announce big shareholder payouts as Fed eases stress tests
Wall Street's major banks, including JPMorgan and Goldman Sachs, announced significant shareholder payouts after passing relaxed regulatory stress tests, reflecting a less stringent banking environment post-2008 financial crisis. JPMorgan plans a $50 billion share buyback and increases its dividend to $1.50 per share, while Goldman raises its dividend by 33% to $4, marking a shift towards increased capital returns to shareholders. Explain It To Me Like I'm 5: Big banks are giving more money to...
Read more